Show simple item record

dc.contributor.authorDowling, RJOen_US
dc.contributor.authorKalinsky, Ken_US
dc.contributor.authorHayes, DFen_US
dc.contributor.authorBidard, F-Cen_US
dc.contributor.authorCescon, DWen_US
dc.contributor.authorChandarlapaty, Sen_US
dc.contributor.authorDeasy, JOen_US
dc.contributor.authorDowsett, Men_US
dc.contributor.authorGray, RJen_US
dc.contributor.authorHenry, NLen_US
dc.contributor.authorMeric-Bernstam, Fen_US
dc.contributor.authorPerlmutter, Jen_US
dc.contributor.authorSledge, GWen_US
dc.contributor.authorBratman, SVen_US
dc.contributor.authorCarey, LAen_US
dc.contributor.authorChang, MCen_US
dc.contributor.authorDeMichele, Aen_US
dc.contributor.authorEnnis, Men_US
dc.contributor.authorJerzak, KJen_US
dc.contributor.authorKorde, LAen_US
dc.contributor.authorLohmann, AEen_US
dc.contributor.authorMamounas, EPen_US
dc.contributor.authorParulekar, WRen_US
dc.contributor.authorRegan, MMen_US
dc.contributor.authorSchramek, Den_US
dc.contributor.authorStambolic, Ven_US
dc.contributor.authorThorat, MAen_US
dc.contributor.authorWhelan, TJen_US
dc.contributor.authorWolff, ACen_US
dc.contributor.authorWoodgett, JRen_US
dc.contributor.authorSparano, JAen_US
dc.contributor.authorGoodwin, PJen_US
dc.date.accessioned2020-01-06T11:54:36Z
dc.date.issued2019-12
dc.identifier.citationJNCI cancer spectrum, 2019, 3 (4), pp. pkz050 - ?
dc.identifier.issn2515-5091
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3483
dc.identifier.eissn2515-5091
dc.identifier.doi10.1093/jncics/pkz050
dc.description.abstractDisease recurrence (locoregional, distant) exerts a significant clinical impact on the survival of estrogen receptor-positive breast cancer patients. Many of these recurrences occur late, more than 5 years after original diagnosis, and represent a major obstacle to the effective treatment of this disease. Indeed, methods to identify patients at risk of late recurrence and therapeutic strategies designed to avert or treat these recurrences are lacking. Therefore, an international workshop was convened in Toronto, Canada, in February 2018 to review the current understanding of late recurrence and to identify critical issues that require future study. In this article, the major issues surrounding late recurrence are defined and current approaches that may be applicable to this challenge are discussed. Specifically, diagnostic tests with potential utility in late-recurrence prediction are described as well as a variety of patient-related factors that may influence recurrence risk. Clinical and therapeutic approaches are also reviewed, with a focus on patient surveillance and the implementation of extended endocrine therapy in the context of late-recurrence prevention. Understanding and treating late recurrence in estrogen receptor-positive breast cancer is a major unmet clinical need. A concerted effort of basic and clinical research is required to confront late recurrence and improve disease management and patient survival.
dc.formatElectronic-eCollection
dc.format.extentpkz050 - ?
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleToronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations.
dc.typeJournal Article
dcterms.dateAccepted2019-07-10
rioxxterms.versionofrecord10.1093/jncics/pkz050
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
rioxxterms.licenseref.startdate2019-12
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJNCI cancer spectrum
pubs.issue4
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology/Endocrinology (hon.)
pubs.publication-statusPublished
pubs.volume3
pubs.embargo.termsNo embargo
icr.researchteamEndocrinologyen_US
dc.contributor.icrauthorDowsett, Mitchen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0